Mammary Cell News Volume 6.06 | Feb 20 2014

Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs
Researchers tested whether NAD(P)H:quinone oxidoreductase 1 (NQO1)+ cells generated sufficient H₂O₂ after ß-Lapachone (ß-lap) treatment to elicit bystander effects, DNA damage and cell death in neighboring NQO1low cells. ß-Lap showed NQO1-dependent efficacy against two triple-negative breast cancer xenografts. [Antioxid Redox Signal] Abstract

Expression of Base Excision Repair Key Factors and miR17 in Familial and Sporadic Breast Cancer
The expression of base excision repair enzymes and of the scaffold protein XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1) were investigated in familial and sporadic breast cancer cases. [Cell Death Dis] Full Article

12-O-Tetradecanoylphorbol-13-Acetate Promotes Breast Cancer Cell Motility by Increasing S100A14 Level in a Kruppel-Like Transcription Factor 4 (KLF4)-Dependent Manner
Stable silencing of KLF4 significantly suppressed breast cancer cell migration induced by 12-O-tetradecanoylphorbol-13-acetate. [J Biol Chem] Abstract | Full Article

Bisphenol-A and Diethylstilbestrol Exposure Induces the Expression of Breast Cancer Associated Long Noncoding RNA HOTAIR In Vitro and In Vivo
Scientists investigated if HOTAIR expression is misregulated by bisphenol-A (BPA) and diethylstilbestrol (DES). They demonstrated BPA and DES induce HOTAIR expression in cultured human breast cancer cells as well as in vivo in the mammary glands of rat. [J Steroid Biochem Mol Biol] Abstract

Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
Scientists showed that PUVA exerts antitumor effects in models of human breast cancer that overexpress the ErbB2 receptor tyrosine kinase oncogene, through a new mechanism. Independent of interstrand DNA crosslink formation, the antitumor effects of PUVA in ErbB2+ breast cancer models can instead be mediated through inhibition of ErbB2 activation and signaling. [PLoS One] Full Article | Press Release

The Selective Cytotoxicity Elicited by Phytochemical Extract from Senecio graveolens (Asteraceae) on Breast Cancer Cells Is Enhanced by Hypoxia
The cytotoxic effect of the alcoholic extract from S. graveolens, as well as its most abundant compound 4-hydroxy-3-(3-methyl-2-butenyl)acetophenone, were tested in the breast cancer cell lines and non-tumorigenic MCF-10F cells. Researchers showed that the phytochemical extract was able to induce cytotoxicity in cancer cells but not in MCF-10F. [Int J Oncol] Abstract

RP215 Single Chain Fragment Variable and Single Domain Recombinant Antibodies Induce Cell Cycle Arrest at G0/G1 Phase in Breast Cancer
Researchers aimed to develop the novel recombinant single chain variable fragment-RP215 and single domain-RP215 antibodies based on the variable regions of the RP215 monoclonal antibody against CA215, a pan cancer marker expressed in various human tumor tissues, and to examine their biological activity in breast cancer cell lines. [Mol Immunol] Abstract

Nuclear Factor-?B Plays a Critical Role in Both Intrinsic and Acquired Resistance against Endocrine Therapy in Human Breast Cancer Cells
Researchers focused on roles of nuclear factor-?B (NF-?B) in the hormone dependency of breast cancers by means of estrogen receptor (ER)-positive MCF-7 cells. Blocking of NF-?B signals in ER-negative cells stopped proliferation by downregulation of D-type cyclins. [Sci Rep] Full Article

CLINICAL RESEARCH

Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis
Eradication of tumor from both breast and lymph nodes was better associated with improved event-free survival and overall survival than was tumor eradication from the breast alone. [Lancet] Full Article

Individualized Chemotherapy Based on Organ Selectivity: A Retrospective Study of Vinorelbine and Capecitabine for Patients with Metastatic Breast Cancer
This study proposed a conception of individualized chemotherapy based on organ selectivity of drug distribution by retrospectively comparing the effect of vinorelbine and capecitabine in patients with metastatic breast cancer. [Curr Med Res Opin] Abstract

Win a $25 Amazon Gift Card!
Connexon Creative is evaluating reader interest in a new social media platform. Fill out this quick survey for your chance to win 1 of 4 $25 gift cards! Take survey here

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
New trial confirms MetaSite Breast test’s ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer’s probability of metastasizing. [PR Newswire Association LLC] Press Release

Oncothyreon and Array BioPharma Announce Initiation of Phase Ib Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
Oncothyreon Inc. and Array BioPharma Inc. announced the initiation of a Phase Ib trial of ONT-380 in combination with Kadcyla® in patients with metastatic HER2+ breast cancer. [Oncothyreon Inc.]
Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

PhD Position – Grading CIN in the Mammary Gland (European Molecular Biology Laboratory)

Studentship – Microtubules and End-Binding Proteins in Epithelial Remodeling and Breast Cancer Invasion (University of East Anglia)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Hodgkin Lymphoma and Breast Cancer (Hackensack University Medical Center)

Postdoctoral Position – Functions of Epigenetic Enzymes in Breast Cancer (University of Wisconsin-Madison)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.